[1]

Khan AW, Jandeleit-Dahm KAM. 2025. Atherosclerosis in diabetes mellitus: novel mechanisms and mechanism-based therapeutic approaches. Nature Reviews Cardiology 22(7):482−496

doi: 10.1038/s41569-024-01115-w
[2]

Crunkhorn S. 2025. Blocking ceramide signalling alleviates atherosclerosis. Nature Reviews Drug Discovery 24(5):334

doi: 10.1038/d41573-025-00057-3
[3]

Zhang S, Lin H, Wang J, Rui J, Wang T, et al. 2025. Sensing ceramides by CYSLTR2 and P2RY6 to aggravate atherosclerosis. Nature 641:476−485

doi: 10.1038/s41586-025-08792-8
[4]

Zhu Q, Scherer PE. 2024. Ceramides and atherosclerotic cardiovascular disease: a current perspective. Circulation 149(21):1624−1626

doi: 10.1161/CIRCULATIONAHA.123.065409
[5]

Choi RH, Tatum SM, Symons JD, Summers SA, Holland WL. 2021. Ceramides and other sphingolipids as drivers of cardiovascular disease. Nature Reviews Cardiology 18(10):701−711

doi: 10.1038/s41569-021-00536-1
[6]

Blackburn MR. 2011. P2Y6 and vascular inflammation. Blood 117(8):2304−2305

doi: 10.1182/blood-2011-01-327973
[7]

Li Y, Zhou M, Li H, Dai C, Yin L, et al. 2024. Macrophage P2Y6 receptor deletion attenuates atherosclerosis by limiting foam cell formation through phospholipase Cβ/store-operated calcium entry/calreticulin/scavenger receptor A pathways. European Heart Journal 45(4):268−283

doi: 10.1093/eurheartj/ehad796
[8]

Yang D, Zhou Q, Labroska V, Qin S, Darbalaei S, et al. 2021. G protein-coupled receptors: structure- and function-based drug discovery. Signal Transduction and Targeted Therapy 6(1):7

doi: 10.1038/s41392-020-00435-w
[9]

Moore AR, Ceraudo E, Sher JJ, Guan Y, Shoushtari AN, et al. 2016. Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nature Genetics 48(6):675−680

doi: 10.1038/ng.3549
[10]

de Almeida Carvalho L, Alves VS, Coutinho-Silva R, Savio LEB. 2025. G protein-coupled purinergic P2Y receptors in infectious diseases. Pharmacology & Therapeutics 267:108796

doi: 10.1016/j.pharmthera.2025.108796
[11]

Zhu Y, Zhou M, Cheng X, Wang H, Li Y, et al. 2023. Discovery of selective P2Y6R antagonists with high affinity and in vivo efficacy for inflammatory disease therapy. Journal of Medicinal Chemistry 66(9):6315−6332

doi: 10.1021/acs.jmedchem.3c00210
[12]

Wright SC, Motso A, Koutsilieri S, Beusch CM, Sabatier P, et al. 2023. GLP-1R signaling neighborhoods associate with the susceptibility to adverse drug reactions of incretin mimetics. Nature Communications 14(1):6243

doi: 10.1038/s41467-023-41893-4